Article 19 · 8 min
Mitochondrial-derived peptides in the literature
Humanin, MOTS-c and mitochondria-targeted sequences: what the published research describes and where it stops.
A second genetic compartment
Mitochondrial-derived peptides, often abbreviated MDPs, are a relatively recent class of signalling molecules encoded by short open reading frames within mitochondrial transcripts. Their discovery challenged the older view that mitochondrial DNA encoded only the well-known respiratory-chain proteins, ribosomal RNAs and transfer RNAs. Short open reading frames can produce biologically active micropeptides, and the two most widely discussed examples are Humanin and MOTS-c. This field remains young compared with classical peptide endocrinology, so mechanistic conclusions should be matched carefully to the experimental model.
Humanin
Humanin was identified in the early 2000s through studies of cellular stress and neurodegeneration-related models. It is encoded within the mitochondrial 16S rRNA region, although nuclear copies and isoforms complicate the genetics. Experimental literature describes Humanin in cytoprotective and anti-apoptotic contexts, including interactions with proteins involved in programmed cell death and signalling through cell-surface receptor complexes in some systems. The existence of several proposed receptors and intracellular partners illustrates an important point: MDP mechanisms may be context-dependent rather than reducible to a single receptor pathway.
MOTS-c
MOTS-c was reported in 2015 and is encoded within the 12S rRNA region of mitochondrial DNA. Published studies have linked it to metabolic stress responses, folate and purine metabolism, and AMPK-associated signalling. Some work describes stress-dependent translocation of MOTS-c to the nucleus and changes in gene expression. Animal models have examined glucose handling, exercise-related physiology and age-associated metabolic changes. These findings are mechanistically interesting, but most do not by themselves establish clinically relevant outcomes in humans.
MDPs versus mitochondria-targeted peptides
MDPs should be distinguished from mitochondria-targeted synthetic peptides. Elamipretide, also known historically as SS-31, is not encoded by mitochondrial DNA. It is a synthetic tetrapeptide designed to accumulate at the inner mitochondrial membrane. Literature has focused on interactions with cardiolipin, mitochondrial membrane organisation, electron-transport efficiency and reactive-oxygen-species-related endpoints. Grouping SS-31 with MDPs can be convenient thematically, but technically the categories are different: one concerns endogenous mitochondrial coding, the other molecular targeting of mitochondria.
Measurement challenges
Methodological issues are important in this literature. Measuring tiny peptides in biological matrices is difficult because of rapid degradation, low abundance, antibody specificity and potential interference from homologous sequences. Mass-spectrometric confirmation, carefully validated immunoassays and genetic approaches are therefore particularly valuable. Species differences also matter because mitochondrial genomes and short open reading frames are not always conserved in the same way as canonical nuclear genes.
Evidence tiers
The evidentiary hierarchy remains uneven. Cell-culture experiments can identify stress-response pathways; animal models can show integrated physiological effects; observational human studies may identify associations; and controlled clinical trials are required to test therapeutic outcomes. Findings should not be carried from one tier to another without explicit evidence. A pathway change in a mouse model is not equivalent to a demonstrated human benefit.
Why the field matters
For peptide research, MDPs are important because they broaden the conceptual role of mitochondria from energy-producing organelles to signalling platforms with their own encoded micropeptides. They also illustrate why modern peptide science increasingly overlaps genomics, proteomics and metabolomics. The most defensible summary is that Humanin and MOTS-c have substantial preclinical literatures connecting mitochondrial stress signalling with cellular metabolism and survival, while the translation, receptor biology and clinical significance of many reported effects remain active areas of investigation.
References
- Primary and review literature on mitochondrial-derived peptides Humanin and MOTS-c; much of the evidence base remains preclinical.